Skip to content
Awesome – Lifestyle
Author:
Adlai Nortye Ltd.
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
August 3, 2026
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
July 16, 2026
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
July 13, 2026
Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
April 16, 2026